---
title: "IMAGI INT'L subsidiary issues new shares to exchange for ACESO LIFE SCI 16.67%"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/274421435.md"
description: "IMAGI INT'L announced that its subsidiary Imagi Fin issued new shares to ACESO LIFE SCI for a transaction amount of 177 million yuan, with the subscriber issuing 1.476 billion shares at a price of 0.12 yuan per share. After the transaction is completed, the subscriber will hold approximately 19.74% equity in Imagi Fin, while IMAGI INT'L's shareholding ratio will be diluted from 98.69% to 79.21%, and it will hold 16.67% equity in the subscriber, becoming its major shareholder"
datetime: "2026-02-01T12:04:25.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/274421435.md)
  - [en](https://longbridge.com/en/news/274421435.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/274421435.md)
---

# IMAGI INT'L subsidiary issues new shares to exchange for ACESO LIFE SCI 16.67%

IMAGI INT'L (00585.HK) announced that its subsidiary Imagi Fin will issue new shares to ACESO LIFE SCI (00474.HK) at a price of HKD 177 million, with the subscriber paying for 1.476 billion consideration shares at HKD 0.12 per share. Upon completion, the subscriber will hold approximately 19.74% equity in Imagi Fin, and the company's shareholding will be diluted from 98.69% to 79.21%, while also holding 16.67% equity in the subscriber, becoming its major shareholder

### Related Stocks

- [516930.CN](https://longbridge.com/en/quote/516930.CN.md)
- [159849.CN](https://longbridge.com/en/quote/159849.CN.md)
- [00585.HK](https://longbridge.com/en/quote/00585.HK.md)
- [516500.CN](https://longbridge.com/en/quote/516500.CN.md)
- [00474.HK](https://longbridge.com/en/quote/00474.HK.md)
- [159837.CN](https://longbridge.com/en/quote/159837.CN.md)

## Related News & Research

- [Anthropic adds Novartis CEO Vas Narasimhan to its board](https://longbridge.com/en/news/282719936.md)
- [iSpecimen Reschedules Annual Meeting Amid Ongoing Quorum Challenges](https://longbridge.com/en/news/282588196.md)
- [Cutia Therapeutics’ Botox Rival Meets Phase III Goals in China](https://longbridge.com/en/news/282464943.md)
- [AbbVie bets on Chinese biopharma’s pain pipeline in $745m bid](https://longbridge.com/en/news/282533515.md)
- [EKF Diagnostics boosts sports performance offering with Beep Insights tech deal](https://longbridge.com/en/news/282496132.md)